Early lung injury contributes to lung fibrosis via AT1 receptor in rats

Acta Pharmacologica Sinica

Volumn 28, Issue 2, 2007, Pages 227-237

  Chen, Fang Ping ^a,b   Gong, Li Kun ^a   Zhang, Ling ^c   Wang, Hui ^a,b   Qi, Xin Ming ^a,b   Wu, Xiong Fei ^a,b   Xiao, Ying ^a,b   Cai, Yan ^a,b   Liu, Lin Lin ^a,b   Li, Xiang Hong ^a   Ren, Jin ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SHANGHAI PULMONARY HOSPITAL   (China)

Author keywords

Angiotensin II; AT1 receptor; Lung injury; Pulmonary fibrosis

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; BLEOMYCIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DIPEPTIDYL CARBOXYPEPTIDASE; HYDROXYPROLINE; MALONALDEHYDE; MESSENGER RNA; MYELOPEROXIDASE; VALSARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL COUNT; CHEMICAL ANALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; INFLAMMATORY CELL; LUNG FIBROSIS; LUNG INJURY; LUNG PARENCHYMA; LUNG WEIGHT; MALE; NONHUMAN; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; TISSUE INJURY; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; APOPTOSIS; COLLAGEN; LIPID PEROXIDATION; MALE; PEPTIDYL-DIPEPTIDASE A; PULMONARY FIBROSIS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RNA, MESSENGER; TETRAZOLES; VALINE;

EID: 33846503194     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00493.x     Document Type: Article

References (44)

1. Kelley J. Cytokines of the lung. Am Rev Respir Dis 1990; 141: 765-88.
2. Ward PA, Hunninghake GW. Lung inflammation and fibrosis. Am J Respir Crit Care Med 1998; 157: S123-9.
3. Geiser T. Idiopathic pulmonary fibrosis - a disorder of alveolar wound repair? Swiss Med Wkly 2003; 133: 405-11.
4. Cooper J Jr, White D, Matthay R. Drug-induced pulmonary disease: I. Cytotoxic drugs. Am Rev Respir Dis 1986; 133: 321-40.
5. Thrall RS, Swendsen CL, Shannon TH, Kennedy CA, Frederick DS, Grunze MF, et al. Correlation of changes in pulmonary surfactant phospholipids with compliance in bleomycin-induced pulmonary fibrosis in the rat. Am Rev Respir Dis 1987; 36: 113-8.
6. Thrall RS, McCormick JR, Jack RM, McReynolds RA, Ward PA. Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol 1979; 95: 117-30.
7. Murphy TJ, Takeuchi K, Alexander RW. Molecular cloning of AT1 angiotensin receptors. Am J Hypertens 1992; 5: S236-42.
8. Tanaka A, Matsumori A, Wang W, Sasayama S. An angiotensin II receptor antagonist reduces myocardial damage in an animal model of myocarditis. Circulation 1994; 90: 2051-5.
9. Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 2004; 59: 31-8.
10. Bullock GR, Steyaert I, Bilbe G, Carey RM, Kips J, De Paepe B, et al. Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Biol 2001; 115: 117-24.
11. Marshall RP. The pulmonary renin-angiotensin system. Curr Pharm Des 2003; 9: 715-22.
12. Papp M, Li X, Zhuang J, Wang R, Uhal BD. Angiotensin receptor subtype AT1 mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol 2002; 282: L713-18.
13. Specks U, Martin WJ II, Rohrbach MS. Bronchoalveolar lavage fluid angiotensin-converting enzyme in interstitial lung diseases. Am Rev Respir Dis 1990; 141: 117-23.
14. Song L, Wang D, Cui X, Shi Z, Yang H. Kinetic alterations of angiotensin-II and nitric oxide in radiation pulmonary fibrosis. J Environ Pathol Toxicol Oncol 1998; 17: 141-50.
15. Wang R, Alam G, Zagariya A, Gidea C, Pinillos H, Lalude O, et al. Apoptosis of lung epithelial cells in response to TNF-alpha requires angiotensin II generation de novo. J Cell Physiol 2000; 185: 253-9.
16. Molteni A, Moulder JE, Cohen EF, Ward WF, Fish BL, Taylor JM, et al. Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 2000; 76: 523-32.
17. Szapiel SV, Elson NA, Fulmer JD, Hunninghake GW, Crystal RG. Bleomycin-induced interstitial pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis 1979; 120: 893-9.
18. Brown S, Worsfold M, Sharp C. Microplate assay for the measurement of hydroxyproline in acid-hydrolyzed tissue samples. Biotechniques 2001; 30: 38-40, 42.
19. Gong LK, Li XH, Wang H, Zhang L, Cai Y, Qi XM, et al. Feitai attenuates bleomycin-induced pulmonary fibrosis in rats. Biol Pharm Bull 2004; 27: 634-40.
20. Unger T, Hubner D, Schull B, Yukimura T, Rascher W, Lang RE, et al. Dissociation between in vivo and in vitro measurements of converting enzyme activity after chronic oral treatment with captopril in rats. Am J Cardiol 1982; 49: 1530-2.
21. Stennicke HR, Salvesen GS. Biochemical characteristics of caspases-3, -6, -7, and -8. J Biol Chem 1997; 272: 25 719-23.
22. Takabatake N, Arao T, Sata M, Abe S, Inoue S, Shibata Y, et al. Involvement of pulmonary endothelial cell injury in the pathogenesis of pulmonary fibrosis: clinical assessment by 123I-MIBG lung scintigraphy. Eur J Nucl Med Mol Imaging 2005; 32: 221-8.
23. Kokkonen JO, Saarinen J, Kovanen PT. Angiotensin II formation in the human heart: an ACE or non-ACE-mediated pathway? Ann Med 1998; 30: 9-13.
24. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-8.
25. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745-50.
26. Molteni A, Ward WF, Ts'ao CH, Solliday NH, Dunne M. Monocrotaline-induced pulmonary fibrosis in rats: amelioration by captopril and penicillamine. Proc Soc Exp Biol Med 1985; 180: 112-20.
27. Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 2002; 83: 111-9.
28. Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 1991; 65: 81-94.
29. Wang R, Zagariya A, Ang E, Ibarra-Sunga O, Uhal BD. Fas induced apoptosis of alveolar epithelial cells requires ANG II generation and receptor interaction. Am J Physiol Lung Cell Mol Physiol 1999; 277: L1245-50.
30. Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol 2000; 279: L143-51.
31. Li X, Zhang H, Soledad-Conrad V, Zhuang J, Uhal BD. Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am J Physiol Lung Cell Mol Physiol 2003; 284: L501-7.
32. Lin LY, Lin CY, Su TC, Liau CS. Angiotensin II-induced apoptosis in human endothelial cells is inhibited by adiponectin through restoration of the association between endothelial nitric oxide synthase and heat shock protein 90. FEBS Lett 2004; 574: 106-10.
33. Akishita M, Nagai K, Xi H, Yu W, Sudoh N, Watanabe T, et al. Renin-angiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats. Hypertension 2005; 45: 1188-93.
34. Kuwano K, Hagimoto N, Nakanishi Y. The role of apoptosis in pulmonary fibrosis. Histol Histopathol 2004; 19: 867-81.
35. Gerbitz A, Nickoloff BJ, Olkiewicz K, Willmarth NE, Hildebrandt G, Liu C, et al. A role for tumor necrosis factor-alpha-mediated endothelial apoptosis in the development of experimental idiopathic pneumonia syndrome. Transplantation 2004; 78: 494-502.
36. Liu CY, Liu YH, Lin SM, Yu CT, Wang CH, Lin HC, et al. Apoptotic neutrophils undergoing secondary necrosis induce human lung epithelial cell detachment. J Biomed Sci 2003; 10: 746-56.
37. Lazo JS, Lynch TJ, McCallister J. Bleomycin inhibition of angiotensin-converting enzyme activity from serum, lungs, and cultured pulmonary artery endothelial cells. Am Rev Respir Dis 1986; 134: 73-8.
38. Kinnula VL, Fattman CL, Tan RJ, Oury TD. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005; 172: 417-22.
39. Lenz AG, Hinze-Heyn H, Schneider A, Behr J, Haussinger K, Heindi S, et al. Influence of inflammatory mechanisms on the redox balance in interstitial lung diseases. Respir Med 2004; 98: 737-45.
40. Mastruzzo C, Crimi N, Vancheri C. Role of oxidative stress in pulmonary fibrosis. Monaldi Arch Chest Dis 2002; 57: 173-6.
41. Ullegaddi R, Powers HJ, Gariballa SE. Antioxidant supplementation enhances antioxidant capacity and mitigates oxidative damage following acute ischaemic stroke. Eur J Clin Nutr 2005; 59: 1367-73.
42. Cross CE, Warren D, Gerriets JE, Wilson DW, Halliwell B, Last JA. Deferoxamine injection does not affect bleomycin-induced lung fibrosis in rats. J Lab Clin Med 1985; 106: 433-8.
43. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am J Respir Crit Care Med 2000; 161: 1999-2004.
44. Marshall RP, Gohlke P, Chambers RC, Howell DC, Bottoms SE, Unger T, et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 2004; 286: L156-64.